Skip to main navigation
Skip to search
Skip to main content
University of Kentucky Home
LOGIN & Help
Home
Research units
Researchers
Grants & Contracts
Research output
Facilities & Equipment
Honors & Awards
Activities
Search by expertise, name or affiliation
22-NHL-28-KP-PMC: A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma, ZUMA-22
Iragavarapu, Chaitanya
(PI)
Markey Cancer Center / Cancer Research Priority Initiative
Overview
Grants and Contracts Details
Status
Active
Effective start/end date
3/6/23
→
12/5/23
Funding
Kite Pharma Incorporated:
$18,218.00
View all
View less